Immunotherapy

Name
Immunotherapy
Accession Number
DBCAT005063
Description

Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.

Drugs
DrugDrug Description
Axicabtagene ciloleucelA CAR T cell therapy for relapsed or refractory large B-cell lymphoma, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and diffuse large B-cell lymphoma from follicular lymphoma.
Brexucabtagene autoleucelA modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ζ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma.
NaxitamabA GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
ImlifidaseA cysteine protease that specifically cleaves human IgG antibodies, facilitating kidney transplantation in HLA sensitized patients.
AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease.
Antilymphocyte immunoglobulin (horse)A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients.
Antithymocyte immunoglobulin (rabbit)A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.
RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria.
RilonaceptAn IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder.
RisankizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
SecukinumabAn immunomodulating agent and interleukin antagonist used to manage moderate to severe plaque psoriasis and active psoriatic arthritis or ankylosing spondylitis.
SiltuximabAn interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
SiponimodA medication used to treat relapsing multiple sclerosis.
SirolimusAn immunosuppressant used to prevent organ transplant rejections and to treat lymphangioleiomyomatosis.
SirukumabSirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
ApremilastA non-steroidal medication used for the treatment of inflammatory conditions such as psoriasis and psoriatic arthritis.
AzathioprineAn immunosuppressant used to prevent renal transplant rejection, treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
MethotrexateAn antineoplastic agent used the treatment of a wide variety of cancers as well as severe psoriasis, severe rheumatoid arthritis, and juvenile rheumatoid arthritis.
TisagenlecleucelA CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.
Human papillomavirus type 6 L1 capsid protein antigenHuman papillomavirus type 6 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is...
Human papillomavirus type 11 L1 capsid protein antigenHuman papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is...
Human papillomavirus type 16 L1 capsid protein antigenHuman papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is...
Human papillomavirus type 18 L1 capsid protein antigenHuman papillomavirus type 18 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is...
Human papillomavirus type 31 L1 capsid protein antigenHuman papillomavirus type 31 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of...
Human papillomavirus type 33 L1 capsid protein antigenHuman papillomavirus type 33 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of...
Human papillomavirus type 45 L1 capsid protein antigenHuman papillomavirus type 45 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of...
Human papillomavirus type 52 L1 capsid protein antigenHuman papillomavirus type 52L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age...
Human papillomavirus type 58 L1 capsid protein antigenHuman papillomavirus type 58 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of...
Hepatitis B Vaccine (Recombinant)A solution of Hepatitis B surface antigen used to immunize patients against Hepatitis B.
BCG vaccineBCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
Sipuleucel-TAn autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
AvelumabA monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
CemiplimabA programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma.
DurvalumabAn antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
AldesleukinA recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.
Interferon alfa-2aA form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.
Interferon alfa-2bA form of recombinant human interferon used to treat hepatitis B and C infection, genital warts, hairy cell leukemia, follicular lymphoma, malignant melanoma, and AIDs-related Kaposi's sarcoma.
Peginterferon alfa-2bA purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers.
ImiquimodA toll-like receptor 7 agonist used to treat non hyperkeratotic, non hypertrophic actinic keratosis, basal cell carcinoma, genital or perianal warts, and condyloma acuminata.
PexidartinibAn antitumor agent that is used for the treatment of rare disease tenosynovial giant cell tumors (TGCT) by inhibiting colony-stimulating factor 1 and its receptor.
Talimogene laherparepvecA genetically modified virus used to treat recurrent melanoma, or metastatic melanoma.
AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
DaratumumabA CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma.
DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
DinutuximabAn immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
ElotuzumabAn antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
IsatuximabA chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies.
MogamulizumabA monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
OfatumumabAn anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
OlaratumabA platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
RamucirumabAn antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
TafasitamabA CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies.
TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
Belantamab mafodotinAn anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
Ibritumomab tiuxetanA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
Moxetumomab pasudotoxA CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment.
Polatuzumab vedotinA CD79b antibody conjugate indicated to treat relapsed or refractory B-cell lymphoma.
Sacituzumab govitecanSacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.[L13002]
Trastuzumab deruxtecanAn antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
BlinatumomabAn antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
PentostatinAn adenosine deaminase inhibitor used to treat hairy cell leukemia.
PomalidomideA thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma.
Ropeginterferon alfa-2bRopeginterferon alfa-2b is under investigation in clinical trial NCT01949805 (Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera).
RuxolitinibA kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.
CatumaxomabFor use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
MifamurtideA muramyl dipeptide derivative used to treat high grade, resectable, non-metastatic osteosarcoma after surgical resection.
EverolimusA mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies.
Denileukin diftitoxA recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor.
EdrecolomabNot Annotated
EfalizumabA monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
IbrutinibAn antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia.
IdelalisibAn antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL).
ImatinibA tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.
BelinostatA histone deacetylase (HDAC) inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
VedolizumabAn integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.
Lisocabtagene maraleucelA CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas.
Idecabtagene vicleucelAn autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma.
Drugs & Drug Targets
DrugTargetType
Axicabtagene ciloleucelB-lymphocyte antigen CD19target
Brexucabtagene autoleucelB-lymphocyte antigen CD19target
NaxitamabGD2 disialogangliosidetarget
ImlifidaseIgG heavy chaintarget
AnakinraInterleukin-1 receptor type 1target
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
RavulizumabComplement C5target
RilonaceptInterleukin-1 betatarget
RilonaceptInterleukin-1 alphatarget
RilonaceptInterleukin-1 receptor antagonist proteintarget
RisankizumabInterleukin-23target
SarilumabCytochrome P450 3A4enzyme
SarilumabInterleukin-6 receptor subunit alphatarget
SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
SecukinumabInterleukin-17Atarget
SiltuximabInterleukin-6target
SiltuximabCytochrome P450 3A4enzyme
SiponimodSphingosine 1-phosphate receptor 5target
SiponimodSphingosine 1-phosphate receptor 1target
SiponimodCytochrome P450 3A4enzyme
SiponimodCytochrome P450 2C9enzyme
SirolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
SirolimusCytochrome P450 3A4enzyme
SirolimusSerine/threonine-protein kinase mTORtarget
SirolimusFibroblast growth factor 2target
SirolimusCytochrome P450 3A5enzyme
SirolimusCytochrome P450 3A7enzyme
SirolimusP-glycoprotein 1transporter
SirolimusSolute carrier organic anion transporter family member 1B1transporter
SirolimusMultidrug and toxin extrusion protein 1transporter
ApremilastPhosphodiesterase isozyme 4target
ApremilastCytochrome P450 3A4enzyme
ApremilastCytochrome P450 2A6enzyme
ApremilastCytochrome P450 1A2enzyme
ApremilastP-glycoprotein 1transporter
AzathioprineThiopurine S-methyltransferaseenzyme
AzathioprineXanthine dehydrogenase/oxidaseenzyme
AzathioprineGlutathione S-transferase A1enzyme
AzathioprineGlutathione S-transferase A2enzyme
AzathioprineGlutathione S-transferase Mu 1enzyme
AzathioprineRas-related C3 botulinum toxin substrate 1target
AzathioprineCytochrome P450 1A2enzyme
AzathioprineHypoxanthine-guanine phosphoribosyltransferaseenzyme
AzathioprineNucleotide triphosphate diphosphatase NUDT15enzyme
AzathioprineEquilibrative nucleoside transporter 2transporter
AzathioprineSolute carrier family 28 member 3transporter
AzathioprineP-glycoprotein 1transporter
AzathioprineSolute carrier family 43 member 3transporter
AzathioprineSerum albumincarrier
AzathioprineInosine-5'-monophosphate dehydrogenase 1enzyme
AzathioprineInosine-5'-monophosphate dehydrogenase 2enzyme
AzathioprineGMP synthase [glutamine-hydrolyzing]enzyme
AzathioprineInosine triphosphate pyrophosphataseenzyme
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
EculizumabComplement C5target
MethotrexateDihydrofolate reductasetarget
MethotrexateAldehyde oxidaseenzyme
MethotrexateMethylenetetrahydrofolate reductaseenzyme
MethotrexateSerum albumincarrier
MethotrexateCanalicular multispecific organic anion transporter 2transporter
MethotrexateMultidrug resistance-associated protein 4transporter
MethotrexateMultidrug resistance-associated protein 1transporter
MethotrexateSolute carrier family 22 member 6transporter
MethotrexateMultidrug resistance-associated protein 7transporter
MethotrexateSolute carrier family 22 member 8transporter
MethotrexateCanalicular multispecific organic anion transporter 1transporter
MethotrexateP-glycoprotein 1transporter
MethotrexateSolute carrier organic anion transporter family member 1A2transporter
MethotrexateMonocarboxylate transporter 1transporter
MethotrexateATP-binding cassette sub-family C member 11transporter
MethotrexateSolute carrier organic anion transporter family member 1B3transporter
MethotrexateSolute carrier family 22 member 11transporter
MethotrexateSolute carrier organic anion transporter family member 1C1transporter
MethotrexateSolute carrier organic anion transporter family member 3A1transporter
MethotrexateATP-binding cassette sub-family G member 2transporter
MethotrexateSolute carrier family 22 member 7transporter
MethotrexateSolute carrier organic anion transporter family member 1B1transporter
Methotrexate6-phosphogluconate dehydrogenase, decarboxylatingenzyme
MethotrexateProton-coupled folate transportertransporter
MethotrexateFolylpolyglutamate synthase, mitochondrialenzyme
MethotrexateGamma-glutamyl hydrolaseenzyme
MethotrexateDihydrofolate reductaseenzyme
MethotrexateThymidylate synthaseenzyme
MethotrexateBifunctional purine biosynthesis protein PURHenzyme
MethotrexateSolute carrier organic anion transporter family member 4C1transporter
MethotrexateFolate transporter 1transporter
MethotrexateFolate receptor alphatransporter
MethotrexateCytochrome P450 3A4enzyme
MethotrexateThymidylate synthasetarget
MethotrexateBifunctional purine biosynthesis protein PURHtarget
MethotrexateFolate receptor betatransporter
MethotrexateSolute carrier family 15 member 1transporter
MethotrexateProton-coupled amino acid transporter 1transporter
TisagenlecleucelB-lymphocyte antigen CD19target
Sipuleucel-TProstatic acid phosphatasetarget
AtezolizumabProgrammed cell death 1 ligand 1target
AvelumabProgrammed cell death 1 ligand 1target
CemiplimabProgrammed cell death protein 1target
DurvalumabProgrammed cell death 1 ligand 1target
IpilimumabCytotoxic T-lymphocyte protein 4target
NivolumabProgrammed cell death protein 1target
PembrolizumabProgrammed cell death protein 1target
AldesleukinInterleukin-2 receptor subunit betatarget
AldesleukinInterleukin-2 receptor subunit alphatarget
AldesleukinCytokine receptor common subunit gammatarget
AldesleukinProstaglandin G/H synthase 2enzyme
AldesleukinCytosolic phospholipase A2enzyme
AldesleukinCytochrome P450 3A4enzyme
AldesleukinXanthine dehydrogenase/oxidaseenzyme
AldesleukinCytochrome P450 2E1enzyme
Interferon alfa-2aInterferon alpha/beta receptor 1target
Interferon alfa-2aInterferon alpha/beta receptor 2target
Interferon alfa-2aCytochrome P450 1A2enzyme
Interferon alfa-2bInterferon alpha/beta receptor 2target
Interferon alfa-2bInterferon alpha/beta receptor 1target
Interferon alfa-2bCytochrome P450 1A2enzyme
Peginterferon alfa-2bInterferon alpha/beta receptor 1target
Peginterferon alfa-2bInterferon alpha/beta receptor 2target
Peginterferon alfa-2bCytochrome P450 1A2enzyme
Peginterferon alfa-2bCytochrome P450 2D6enzyme
Peginterferon alfa-2bCytochrome P450 2C9enzyme
ImiquimodToll-like receptor 7target
ImiquimodToll-like receptor 8target
ImiquimodCytochrome P450 3A4enzyme
PexidartinibCytochrome P450 3A4enzyme
PexidartinibUDP-glucuronosyltransferase 1-4enzyme
PexidartinibMacrophage colony-stimulating factor 1 receptortarget
PexidartinibCytochrome P450 2B6enzyme
PexidartinibCytochrome P450 2C9enzyme
PexidartinibUDP-glucuronosyltransferase 1-1enzyme
PexidartinibMultidrug and toxin extrusion protein 1transporter
PexidartinibMultidrug and toxin extrusion protein 2transporter
PexidartinibSolute carrier organic anion transporter family member 1B1transporter
PexidartinibSolute carrier organic anion transporter family member 1B3transporter
PexidartinibSolute carrier organic anion transporter family member 2B1transporter
PexidartinibSerum albumincarrier
PexidartinibAlpha-1-acid glycoprotein 1carrier
PexidartinibMast/stem cell growth factor receptor Kittarget
PexidartinibReceptor-type tyrosine-protein kinase FLT3target
PexidartinibPlatelet-derived growth factor receptor betatarget
Talimogene laherparepvecHeparan sulfatetarget
Talimogene laherparepvecDNA polymerase catalytic subunittarget
Talimogene laherparepvecDNA polymerase catalytic subunittarget
AlemtuzumabCAMPATH-1 antigentarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabVascular endothelial growth factor Atarget
BevacizumabComplement C1q subcomponent subunit Atarget
BevacizumabComplement C1q subcomponent subunit Btarget
BevacizumabComplement C1q subcomponent subunit Ctarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabEpidermal growth factor receptortarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CetuximabComplement C1q subcomponent subunit Atarget
CetuximabComplement C1q subcomponent subunit Btarget
CetuximabComplement C1q subcomponent subunit Ctarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DaratumumabADP-ribosyl cyclase 1target
DenosumabTumor necrosis factor ligand superfamily member 11target
DinutuximabGD2 disialogangliosidetarget
ElotuzumabSLAM family member 7target
IsatuximabADP-ribosyl cyclase 1target
MogamulizumabC-C chemokine receptor type 4target
NecitumumabEpidermal growth factor receptortarget
ObinutuzumabB-lymphocyte antigen CD20target
OfatumumabB-lymphocyte antigen CD20target
OlaratumabPlatelet-derived growth factor receptor alphatarget
PanitumumabEpidermal growth factor receptortarget
PertuzumabReceptor tyrosine-protein kinase erbB-2target
RamucirumabVascular endothelial growth factor receptor 2target
RituximabB-lymphocyte antigen CD20target
TafasitamabB-lymphocyte antigen CD19target
TrastuzumabReceptor tyrosine-protein kinase erbB-2target
Belantamab mafodotinSolute carrier organic anion transporter family member 1B1transporter
Belantamab mafodotinSolute carrier organic anion transporter family member 1B3transporter
Belantamab mafodotinMultidrug resistance-associated protein 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 2transporter
Belantamab mafodotinBile salt export pumptransporter
Belantamab mafodotinP-glycoprotein 1transporter
Belantamab mafodotinTumor necrosis factor receptor superfamily member 17target
Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
Brentuximab vedotinCytochrome P450 3A4enzyme
Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
Enfortumab vedotinCytochrome P450 3A4enzyme
Enfortumab vedotinNectin-4target
Enfortumab vedotinP-glycoprotein 1transporter
Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
Ibritumomab tiuxetanB-lymphocyte antigen CD20target
Inotuzumab ozogamicinP-glycoprotein 1transporter
Inotuzumab ozogamicinB-cell receptor CD22target
Moxetumomab pasudotoxB-cell receptor CD22target
Moxetumomab pasudotoxElongation factor 2target
Polatuzumab vedotinCytochrome P450 3A4enzyme
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintransporter
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintarget
Sacituzumab govitecanTumor-associated calcium signal transducer 2target
Sacituzumab govitecanDNA topoisomerase 1target
Sacituzumab govitecanFar upstream element-binding protein 1target
Sacituzumab govitecanUDP-glucuronosyltransferase 1-1enzyme
Trastuzumab deruxtecanP-glycoprotein 1transporter
Trastuzumab deruxtecanHigh affinity immunoglobulin gamma Fc receptor Itarget
Trastuzumab deruxtecanDNA topoisomerase 1target
Trastuzumab deruxtecanLysosomal alpha-glucosidaseenzyme
Trastuzumab deruxtecanDNA topoisomerase 1enzyme
Trastuzumab deruxtecanCathepsin Benzyme
Trastuzumab deruxtecanCathepsin L1enzyme
Trastuzumab deruxtecanCytochrome P450 3A4enzyme
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B1transporter
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B3transporter
Trastuzumab deruxtecanMultidrug and toxin extrusion protein 2transporter
Trastuzumab deruxtecanMultidrug resistance-associated protein 1transporter
Trastuzumab deruxtecanATP-binding cassette sub-family G member 2transporter
Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
Trastuzumab emtansineP-glycoprotein 1transporter
Trastuzumab emtansineCytochrome P450 3A4enzyme
Trastuzumab emtansineCytochrome P450 3A5enzyme
BlinatumomabB-lymphocyte antigen CD19target
BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
PentostatinAdenosine deaminasetarget
PomalidomideCytochrome P450 1A2enzyme
PomalidomideCytochrome P450 3A4enzyme
PomalidomideP-glycoprotein 1transporter
PomalidomideProtein cereblontarget
PomalidomideTumor necrosis factortarget
PomalidomideProstaglandin G/H synthase 2target
Ropeginterferon alfa-2bCytochrome P450 1A2enzyme
Ropeginterferon alfa-2bCytochrome P450 2D6enzyme
RuxolitinibTyrosine-protein kinase JAK1target
RuxolitinibTyrosine-protein kinase JAK2target
RuxolitinibCytochrome P450 3A4enzyme
RuxolitinibCytochrome P450 2C9enzyme
RuxolitinibSerum albumincarrier
RuxolitinibTyrosine-protein kinase JAK3target
RuxolitinibNon-receptor tyrosine-protein kinase TYK2target
CatumaxomabEpithelial cell adhesion moleculetarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CatumaxomabT-cell surface glycoprotein CD3 epsilon chaintarget
CatumaxomabHigh affinity immunoglobulin gamma Fc receptor Itarget
DaclizumabInterleukin-2 receptor subunit alphatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DaclizumabComplement C1r subcomponenttarget
DaclizumabComplement C1q subcomponent subunit Atarget
DaclizumabComplement C1q subcomponent subunit Btarget
DaclizumabComplement C1q subcomponent subunit Ctarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DaclizumabInterleukin-2 receptor subunit betatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
MifamurtideToll-like receptor 4target
MifamurtideNucleotide-binding oligomerization domain-containing protein 2target
EverolimusSerine/threonine-protein kinase mTORtarget
EverolimusCytochrome P450 3A4enzyme
EverolimusSolute carrier organic anion transporter family member 1B1transporter
EverolimusSolute carrier organic anion transporter family member 1B3transporter
EverolimusSolute carrier organic anion transporter family member 1A2transporter
EverolimusCytochrome P450 2D6enzyme
EverolimusP-glycoprotein 1transporter
Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
Denileukin diftitoxCytokine receptor common subunit gammatarget
Denileukin diftitoxInterleukin-2 receptor subunit betatarget
EfalizumabIntegrin alpha-Ltarget
EfalizumabIntegrin alpha-Xtarget
IbrutinibTyrosine-protein kinase BTKtarget
IbrutinibCytochrome P450 3A4enzyme
IbrutinibCytochrome P450 3A5enzyme
IbrutinibSerum albumincarrier
Ibrutinibalpha1-acid glycoproteincarrier
IbrutinibCytochrome P450 2D6enzyme
IdelalisibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
IdelalisibATP-binding cassette sub-family G member 2transporter
IdelalisibP-glycoprotein 1transporter
IdelalisibAldehyde oxidaseenzyme
IdelalisibCytochrome P450 2C8enzyme
IdelalisibCytochrome P450 2C19enzyme
IdelalisibCytochrome P450 2B6enzyme
IdelalisibCytochrome P450 3A4enzyme
IdelalisibSolute carrier organic anion transporter family member 1B1transporter
IdelalisibSolute carrier organic anion transporter family member 1B3transporter
IdelalisibCytochrome P450 3A5enzyme
IdelalisibCytochrome P450 3A43enzyme
IdelalisibCytochrome P450 3A7enzyme
IdelalisibUDP-glucuronosyltransferase 1-4enzyme
ImatinibPlatelet-derived growth factor receptor betatarget
ImatinibTyrosine-protein kinase ABL1target
ImatinibMast/stem cell growth factor receptor Kittarget
ImatinibRET proto-oncogenetarget
ImatinibHigh affinity nerve growth factor receptortarget
ImatinibMacrophage colony-stimulating factor 1 receptortarget
ImatinibPlatelet-derived growth factor receptor alphatarget
ImatinibEpithelial discoidin domain-containing receptor 1target
ImatinibCytochrome P450 3A4enzyme
ImatinibBreakpoint cluster region proteintarget
ImatinibCytochrome P450 1A2enzyme
ImatinibCytochrome P450 2D6enzyme
ImatinibCytochrome P450 2C9enzyme
ImatinibCytochrome P450 2C19enzyme
ImatinibCytochrome P450 3A5enzyme
ImatinibCytochrome P450 3A7enzyme
ImatinibSolute carrier family 22 member 1transporter
ImatinibP-glycoprotein 1transporter
ImatinibSolute carrier family 22 member 2transporter
ImatinibATP-binding cassette sub-family G member 2transporter
ImatinibATP-binding cassette sub-family A member 3transporter
ImatinibProstaglandin G/H synthase 1enzyme
ImatinibSerum albumincarrier
ImatinibAlpha-1-acid glycoprotein 1carrier
ImatinibBile salt export pumptransporter
ImatinibCytochrome P450 2C8enzyme
BelinostatHistone deacetylasetarget
BelinostatCytochrome P450 1A2enzyme
BelinostatUDP-glucuronosyltransferase 1-1enzyme
BelinostatCytochrome P450 2C8enzyme
BelinostatCytochrome P450 2C9enzyme
BelinostatP-glycoprotein 1transporter
BelinostatCytochrome P450 3A4enzyme
VedolizumabIntegrin alpha-4target
VedolizumabIntegrin beta-7target
Lisocabtagene maraleucelB-lymphocyte antigen CD19target
Idecabtagene vicleucelTumor necrosis factor receptor superfamily member 17target